Clinical Trials Logo

Inflammatory Response clinical trials

View clinical trials related to Inflammatory Response.

Filter by:

NCT ID: NCT04310423 Completed - Clinical trials for Alcohol Use Disorder

An Inflammatory Challenge Using Endotoxin

Start date: October 19, 2021
Phase: Phase 2
Study type: Interventional

The study design consists of a randomized, double-blind, placebo-controlled trial of low dose endotoxin. The low dose endotoxin challenge induces a transient systemic inflammatory response with normalization of cytokine levels within hours. This "phasic" inflammation is distinct from chronic ("tonic") levels of inflammation that may be present with AUD. A total of 38 non-treatment seeking heavy drinking men and women and 38 light drinking healthy controls will participate in the study. Recruitment will be monitored to ensure the two groups are matched by gender. Eligible participants will be randomly assigned, stratified by gender and BDI-II severity, to receive a single I.V. infusion of either low dose endotoxin (0.8 ng/kg of body weight) or placebo (same volume of 0.9% saline solution) at the UCLA Outpatient Clinical and Translational Research Center (CTRC). All participants will complete an alcohol cue-exposure paradigm and reward responsiveness assessment 2 hours post infusion, which is the time of expected peak cytokine response. All participants will also complete an fMRI alcohol cue-reactivity paradigm at 3 hours post infusion. Plasma levels of proinflammatory cytokines [i.e., Interleukin-6 (IL-6) and tumor necrosis factor-α (TNF- α)], mood, and alcohol craving, will be assessed at baseline and then hourly for four hours post infusion.

NCT ID: NCT04307979 Recruiting - Clinical trials for Inflammatory Response

Acute High Fat Bulletproof Coffee vs Black Coffee on Metabolism, Inflammation and Cognitive Function in Healthy Adults

Start date: January 1, 2020
Phase: N/A
Study type: Interventional

This study will determine whether acute ingestion of a high fat "Bulletproof Coffee" will lead to changes in plasma triglycerides, immune cell function, as well as cognitive function when compared to a black coffee.

NCT ID: NCT04281888 Not yet recruiting - Clinical trials for Inflammatory Response

Inflammatory Anemia Associated Parameters in Septic Patients

Start date: March 20, 2020
Phase:
Study type: Observational

1. To observe the changes in the inflammatory anemiaassociated parameters of patients with sepsis in the early stage of intensive care unit (ICU) admission. 2. To evaluate their association with 28-days mortality 3. To evaluate the effect of blood transfusion on these parameters and the survival of the studied patients

NCT ID: NCT04269876 Terminated - Inflammation Clinical Trials

A Study to Evaluate the Effects of a Marine Lipid Oil Concentrate Formulation on Inflammation

Start date: October 31, 2019
Phase: N/A
Study type: Interventional

To assess the efficacy and safety of a Marine Lipid Oil Concentrate formulation on inflammatory biomarkers and overall well-being in male and female subjects who are overweight to mildly obese, but otherwise generally healthy.

NCT ID: NCT04267705 Active, not recruiting - Clinical trials for Inflammatory Response

Pulses Consumption and Its Role in Managing Systemic Inflammation, Insulin Sensitivity and Gut Microbiome in Human

PS
Start date: February 24, 2020
Phase: N/A
Study type: Interventional

Objective 1: Characterize indices of systemic inflammation and gut microbiota composition and function after chronic (12 weeks) intake of pulses compared to control diet in human OW/OB-IR participants. Objective 2: Characterize dietary- and microbial-derived metabolite pools after regular intake of pulses (12 weeks) in human participants with OW/OB-IR compared to control diet. Objective 3: Characterize cognitive functioning after chronic (12 weeks) intake of pulses compared to control diet in human OW/OB-IR participants.

NCT ID: NCT04266665 Completed - Brain Tumor Clinical Trials

Effect of Dexmedetomidine on Brain Homeostasis and Neurocognitive Outcome

Start date: March 12, 2020
Phase: Phase 4
Study type: Interventional

Brain tumor surgery is commonly associated with different degrees of preoperative intracranial hypertension and surrounding tumor edema, elicited by tumor underlying pathophysiology. During craniotomy for brain tumor resection maintenance of hemodynamic stability and intracranial homoeostasis is of paramount importance. Disordered hemodynamics or adverse stress may activate the immune inflammation or neuroendocrine responses and lead to a surge of inflammatory mediators and stress hormones, which are implicated in secondary brain insults. Adverse physiological responses caused by intraoperative disordered hemodynamics or surgery-related damage, may lead to some secondary brain injury (such as cerebral edema or cerebral hemorrhage), aggravating damage to brain tissue and affecting the recovery from anesthesia, cognition and prognosis in patients. Prevention of secondary brain injury is a key-endpoint to improve clinical outcomes in glioma patients undergoing craniotomy. Alpha2-adrenoceptor agonists have been widely used for sedation, analgesia and anti-sympathetic actions for many years, but the definite evidence of their potential use as neuroprotectants has so far been confined to animal studies, yet the findings are inconsistent. Dexmedetomidine (DEX) has been demonstrated to be a new type a2 adrenergic receptor (a2-AR) agonist, which can selectively bind with the a1 and a2 adrenergic receptor, and playing a dual role by restraining the activity of sympathetic nervous and stimulating the vagus nerve. Dexmedetomidine (DEX) also plays an important role in in inhibiting inflammatory and neuroendocrine responses. Animal experiments showed that the right must have a dexmedetomidine neuro-protective effect. However, the brain-protective effect of dexmedetomidine in anesthesia of craniotomy resection of glioma has not been reported. Thus, the aim of this study was to explore the effect of dexmedetomidine on perioperative brain protection, as well as cerebral oxygenation and metabolic status aiming to provide a basis for clinical rational drug use in patients undergoing craniotomy resection of glioma.

NCT ID: NCT04259125 Active, not recruiting - Epilepsy Clinical Trials

Evaluating the Role of Inflammation in Neonatal Epileptogenesis

NSR-RISE
Start date: December 15, 2018
Phase:
Study type: Observational

The purpose of this study evaluate the relationship between inflammation and epilepsy in neonates with seizures after birth.

NCT ID: NCT04252651 Recruiting - Clinical trials for Deep Vein Thrombosis

Association of Cytokines With the Development of Complications in Burn and Toxic Epidermal Necrolysis (TENS) Patients

Start date: October 2, 2019
Phase:
Study type: Observational

This study will involve blood draws to test for specific cytokines. The study goal is to gain a better understanding of the role of inflammatory response in the development of specific complications in burn and TENS patients.

NCT ID: NCT04247009 Completed - Clinical trials for Arthritis, Rheumatoid

Postprandial Inflammation in Rheumatoid Arthritis

PIRA
Start date: February 1, 2020
Phase: N/A
Study type: Interventional

Patients with RA will be studied to see whether meals of different content will affect inflammation and metabolic variables in the postprandial state. Healthy controls will also be invited to examine potentially different responses to patients with RA.

NCT ID: NCT04232904 Recruiting - Clinical trials for Inflammatory Response

Effect of Transversus Abdominis Plane Block on Anti-inflammatory Response

Start date: December 2, 2019
Phase: Phase 4
Study type: Interventional

The liver transplantation is the only treatment for end-stage liver failure. Lack of sufficient organs from the cadaver to meet the organ needs has increased the interest in a live organ donor transplantation. A peripheral nerve block, transversus abdominous plane block (TAP block); When combined with general anesthesia in live liver donors, it has been shown to significantly reduce perioperative and postoperative opioid consumption, provide shorter recovery time and shorten hospital stay. It has been shown that regional block techniques using local anesthetics and analgesic adjuvants modulate both local and systemic inflammatory reactions caused by surgical injury. Cytokines are important mediators of local and systemic inflammatory response including hyperalgesia after surgery. In literature, the effect of TAP block on anti-inflammatory cytokines in live liver donors was not shown. The aim of this study is to investigate the effect of bupivacaine TAP block on antiflammatory response in living liver donors.